当前位置: 首页 >> 检索结果
161. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
作者: Philip J Mease.;Akihiko Asahina.;Dafna D Gladman.;Yoshiya Tanaka.;William Tillett.;Barbara Ink.;Deepak Assudani.;Christine de la Loge.;Jason Coarse.;Jason Eells.;Laure Gossec.
来源: Rheumatology (Oxford). 2023年62卷2期617-628页
Evaluate effects of long-term bimekizumab treatment on patient-reported outcome (PRO) measures, symptoms and the impact of PsA on patients.
162. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
作者: Laura C Coates.;Christopher T Ritchlin.;Laure Gossec.;Philip S Helliwell.;Proton Rahman.;Alexa P Kollmeier.;Xie L Xu.;May Shawi.;Chetan S Karyekar.;Christine Contré.;Wim Noël.;Shihong Sheng.;Yanli Wang.;Stephen Xu.;Philip J Mease.
来源: Rheumatology (Oxford). 2023年62卷2期606-616页
To evaluate the efficacy of guselkumab for the treatment of active PsA utilizing composite indices.
163. Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial.
作者: Veena K Ranganath.;Antonio La Cava.;Sitaram Vangala.;Jenny Brook.;Tanaz A Kermani.;Daniel E Furst.;Mihaela Taylor.;Gurjit S Kaeley.;Catherine Carpenter.;David A Elashoff.;Zhaoping Li.
来源: Rheumatology (Oxford). 2023年62卷2期565-574页
To examine whether a weight loss intervention programme improves RA disease activity and/or musculoskeletal ultrasound synovitis measures in obese RA patients.
164. Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.
作者: Christopher P Denton.;Francesco Del Galdo.;Dinesh Khanna.;Madelon C Vonk.;Lorinda Chung.;Sindhu R Johnson.;John Varga.;Daniel E Furst.;Jane Temple.;Chiara Zecchin.;Eszter Csomor.;Amy Lee.;Nicolas Wisniacki.;Shaun M Flint.;Juliet Reid.
来源: Rheumatology (Oxford). 2022年62卷1期234-242页
The cytokine oncostatin M (OSM) is implicated in the pathology of SSc. Inhibiting OSM signalling using GSK2330811 (an anti-OSM monoclonal antibody) in patients with SSc has the potential to slow or stop the disease process.
165. The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial.
作者: Sophie I E Liem.;Eva M Hoekstra.;Femke Bonte-Mineur.;César Magro Checa.;Anne Schouffoer.;Cornelia F Allaart.;Tom W J Huizinga.;Sytske Anne Bergstra.;Jeska K de Vries-Bouwstra.
来源: Rheumatology (Oxford). 2023年62卷SI期SI74-SI81页
Silver fibre gloves transport heat from the palm to the fingers, possibly reducing the burden of RP in SSc patients. We aim to evaluate the clinical efficiency of this intervention.
166. The effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome: 24-month follow-up of a randomized trial.
作者: Claire Burton.;Trishna Rathod-Mistry.;Steven Blackburn.;Milica Blagojevic-Bucknall.;Linda Chesterton.;Graham Davenport.;Krysia Dziedzic.;Adele Higginbottom.;Sue Jowett.;Helen Myers.;Raymond Oppong.;Danielle van der Windt.;Elaine Hay.;Edward Roddy.
来源: Rheumatology (Oxford). 2023年62卷2期546-554页
This follow-up study of the INSTinCTS (INjection vs SplinTing in Carpal Tunnel Syndrome) trial compared the effects of corticosteroid injection (CSI) and night splinting (NS) for the initial management of mild-to-moderate CTS on symptoms, resource use and carpal tunnel surgery, over 24 months.
167. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
作者: Elizabeth Price.;Michele Bombardieri.;Alan Kivitz.;Franziska Matzkies.;Oksana Gurtovaya.;Alena Pechonkina.;Wendy Jiang.;Bryan Downie.;Anubhav Mathur.;Afsaneh Mozaffarian.;Neelufar Mozaffarian.;J Eric Gottenberg.
来源: Rheumatology (Oxford). 2022年61卷12期4797-4808页
The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS.
168. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
作者: Walter P Maksymowych.;Rebecca Bolce.;Gaia Gallo.;Emily Seem.;Vladimir J Geneus.;David M Sandoval.;Mikkel Østergaard.;Kurisu Tada.;Xenofon Baraliakos.;Atul Deodhar.;Lianne S Gensler.
来源: Rheumatology (Oxford). 2022年61卷11期4324-4334页
To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial SpA (r-axSpA) and elevated or normal/low baseline inflammation measured by serum CRP or spinal MRI using data from two randomized, double-blind, placebo (PBO)-controlled phase III trials.
169. Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial.
作者: Naoki Kimura.;Takuya Kawahara.;Yukari Uemura.;Tatsuya Atsumi.;Takayuki Sumida.;Toshihde Mimura.;Yasushi Kawaguchi.;Hirofumi Amano.;Yukiko Iwasaki.;Yuko Kaneko.;Toshihiro Matsui.;Yoshinao Muro.;Yoshitaka Imura.;Takashi Kanda.;Yoshiya Tanaka.;Atsushi Kawakami.;Masatoshi Jinnin.;Tomonori Ishii.;Keiju Hiromura.;Yusuke Miwa.;Hiroshi Nakajima.;Masataka Kuwana.;Yasuhiko Nishioka.;Akio Morinobu.;Hideto Kameda.;Hitoshi Kohsaka.
来源: Rheumatology (Oxford). 2022年61卷11期4445-4454页
To assess the efficacy and safety of branched chain amino acids (BCAAs) in the treatment of PM/DM prior to official approval of their use in Japan.
170. Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study).
作者: Clémence David.;Nicolas Duployez.;Philippine Eloy.;Drifa Belhadi.;Julie Chezel.;Véronique Le Guern.;Cédric Laouénan.;Laurène Fenwarth.;Diane Rouzaud.;Alexis Mathian.;Sébastien de Almeida Chaves.;Pierre Duhaut.;Olivier Fain.;Lionel Galicier.;Pascale Ghillani-Dalbin.;Jean Emmanuel Kahn.;Nathalie Morel.;Laurent Perard.;Micheline Pha.;Francoise Sarrot-Reynauld.;Olivier Aumaitre.;François Chasset.;Nicolas Limal.;Helene Desmurs-Clavel.;Felix Ackermann.;Zahir Amoura.;Thomas Papo.;Claude Preudhomme.;Nathalie Costedoat-Chalumeau.;Karim Sacre.
来源: Rheumatology (Oxford). 2022年61卷11期4355-4363页
The detection of somatic mutations among the genes of myeloid cells in asymptomatic patients-defining clonal haematopoiesis of indeterminate potential (CHIP)-is associated with a predisposition to cardiovascular events (CVEs) in the general population. We aimed to determine whether CHIP was associated with CVEs in SLE patients.
171. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
作者: Elizabeth R Volkmann.;Michael Kreuter.;Anna M Hoffmann-Vold.;Marlies Wijsenbeek.;Vanessa Smith.;Dinesh Khanna.;Christopher P Denton.;Wim A Wuyts.;Corinna Miede.;Margarida Alves.;Steven Sambevski.;Yannick Allanore.
来源: Rheumatology (Oxford). 2022年61卷11期4397-4408页
The aim of these analyses was to investigate the rate of decline in forced vital capacity (FVC) in patients with SSc-associated interstitial lung disease (SSc-ILD) with and without cough or dyspnoea in the SENSCIS trial.
172. Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial.
作者: Satoshi Ebata.;Koji Oba.;Kosuke Kashiwabara.;Keiko Ueda.;Yukari Uemura.;Takeyuki Watadani.;Takemichi Fukasawa.;Shunsuke Miura.;Asako Yoshizaki-Ogawa.;Asano Yoshihide.;Ayumi Yoshizaki.;Shinichi Sato.
来源: Rheumatology (Oxford). 2022年61卷11期4364-4373页
The double-blind, parallel-group comparison, investigators initiated phase II clinical trial of IDEC-C2B8 (Rituximab) in patients with Systemic sclerosis (DesiReS) trial showed that rituximab is effective in treating skin sclerosis in SSc. However, which patient groups are likely to benefit from rituximab is unknown.
173. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
作者: Charles G Peterfy.;Vibeke Strand.;Alan Friedman.;Stephen Hall.;Eduardo Mysler.;Patrick Durez.;Xenofon Baraliakos.;Jeffrey V Enejosa.;Tim Shaw.;Yihan Li.;Su Chen.;In-Ho Song.
来源: Rheumatology (Oxford). 2022年61卷8期3246-3256页
To evaluate the inhibition of progression of structural joint damage through week 48 in patients with moderately to severely active RA receiving upadacitinib as monotherapy or in combination with MTX.
174. Efficacy of pulse dexamethasone in non-systemic juvenile idiopathic arthritis: a double-blind randomized controlled trial.
作者: Umang Bhardwaj.;Narendra K Bagri.;Rakesh Lodha.;Sushil K Kabra.;Thirumurthy Velpandian.;Ravindra M Pandey.
来源: Rheumatology (Oxford). 2022年61卷8期3370-3377页
Early aggressive therapy using biologicals is increasingly being used in JIA for early disease remission. Pulse steroids are used in induction regimes for rheumatic disorders such as SLE and systemic JIA; however, no controlled studies have demonstrated their use in non-systemic JIA. The objective of the present study was to evaluate the efficacy and safety of pulse dexamethasone therapy in children with treatment-naïve non-systemic JIA as early aggressive therapy in resource-limited settings.
175. Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort.
作者: Marloes Verstappen.;Xanthe M E Matthijssen.;Annette H M van der Helm-van Mil.
来源: Rheumatology (Oxford). 2022年61卷8期3212-3222页
International guidelines stress timely DMARD initiation in early arthritis as well as when classification criteria are not yet fulfilled. Consequently, undifferentiated arthritis (UA) patients may be increasingly treated with DMARDs. Since UA is a diagnosis of exclusion, the introduction of the 2010 classification criteria presumably decreased the UA population, as former UA patients became regarded as RA. Consequently, the contemporary definition of UA has changed into: no clinical diagnosis and not fulfilling the 1987 nor 2010 RA-criteria. Importantly, placebo-controlled trials on DMARD efficacy in contemporary UA are absent. We aimed to study whether enhanced treatment strategies across the last 25 years improved outcomes in contemporary UA, whereby inclusion period was used as instrumental variable for DMARD treatment.
176. Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis.
作者: Paul Studenic.;Gregor Bond.;Andreas Kerschbaumer.;Manuel Bécède.;Karel Pavelka.;Dmitry Karateev.;Jutta Stieger.;Rudolf Puchner.;Ruediger B Mueller.;Elisabeth Puchhammer-Stöckl.;Martina Durechova.;Michaela Loiskandl.;Thomas Perkmann.;Martina Olejarova.;Elena Luchikhina.;Carl-Walter Steiner.;Michael Bonelli.;Josef S Smolen.;Daniel Aletaha.
来源: Rheumatology (Oxford). 2022年61卷7期2815-2825页
RA patients who fail to respond to MTX can receive biologic dMARDs (bDMARDs). The Torque Teno Virus (TTV) is a potential novel candidate for monitoring of immunosuppression. We explore TTV in these patients and its association with clinical response to bDMARDs.
177. Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.
作者: Xenofon Baraliakos.;Sebastian Kruse.;Simone E Auteri.;Natasha de Peyrecave.;Tommi Nurminen.;Thomas Kumke.;Bengt Hoepken.;Jürgen Braun.
来源: Rheumatology (Oxford). 2022年61卷7期2875-2885页
Fat lesions (FLs) on MRI T1 sequences are considered to be early indicators of structural spinal progression in axial spondyloarthritis (axSpA) patients. In this post-hoc analysis from RAPID-axSpA, we assess whether tumour necrosis factor inhibitor (TNFi) treatment over 4 years impacts FLs in spinal vertebral edges (VEs) of patients with axSpA.
178. 18F-FDG PET-CT in rheumatoid arthritis patients tapering TNFi: reliability, validity and predictive value.
作者: Chantal A M Bouman.;Noortje van Herwaarden.;Annelies B Blanken.;Conny J Van der Laken.;Martin Gotthardt.;Wim J G Oyen.;Alfons A den Broeder.;Aatke van der Maas.;Cornelia H van den Ende.
来源: Rheumatology (Oxford). 2022年61卷SI期SI6-SI13页
To investigate the reliability and validity of fluorine-18 fluorodeoxyglucose (18F-FDG) PET-CT scanning (FDG-PET) in RA patients with low disease activity tapering TNF inhibitors (TNFis) and its predictive value for successful tapering or discontinuation.
179. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.
作者: Frank Behrens.;Philipp Sewerin.;Eugenio de Miguel.;Yusuf Patel.;Anastas Batalov.;Eva Dokoupilova.;Christine Kleinmond.;Effie Pournara.;Ankita Shekhawat.;Claudia Jentzsch.;Annette Wiedon.;Xenofon Baraliakos.; .
来源: Rheumatology (Oxford). 2022年61卷7期2856-2866页
ACHILLES aimed to demonstrate efficacy of secukinumab on Achilles' tendon enthesitis in spondyloarthritis (SpA) patients.
180. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
作者: John H Stone.;Helen Spotswood.;Sebastian H Unizony.;Martin Aringer.;Daniel Blockmans.;Elisabeth Brouwer.;Maria C Cid.;Bhaskar Dasgupta.;Juergen Rech.;Carlo Salvarani.;Robert Spiera.;Min Bao.
来源: Rheumatology (Oxford). 2022年61卷7期2915-2922页
Tocilizumab plus prednisone induces sustained glucocorticoid-free remission in patients with GCA. However, its long-term benefits in new-onset vs relapsing disease are uncertain, and the value of weekly vs every-other-week dosing has not been evaluated.
|